# A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C

> **NCT02564497** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 491 (actual)

## Conditions studied

- Renal Transplantation

## Interventions

- **BIOLOGICAL:** Process E Belatacept
- **BIOLOGICAL:** Process C Belatacept

## Key facts

- **NCT ID:** NCT02564497
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-02
- **Primary completion:** 2017-01-27
- **Final completion:** 2017-01-27
- **Target enrollment:** 491 (ACTUAL)
- **Last updated:** 2019-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02564497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02564497, "A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02564497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*